MOLECURE (WSE: MOC) AND NASDAQ-LISTED BIOTECHNOLOGY COMPANY OCEAN BIOMEDICAL (NASDAQ: OCEA) SIGN AN EXCLUSIVE LICENSING AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF SELECTIVE YKL-40 INHIBITORS.

Reuters · 10/15 11:30

Please log in to view news